AMGEN TO PRESENT AT THE BANK OF AMERICA MERRILL LYNCH GLOBAL HEALTHCARE CONFERENCE
THOUSAND OAKS, Calif., May 7, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Bank of America Merrill Lynch Global Healthcare Conference at 10:00 a.m.
Fiscal Year: January - December
Amgen Inc. (AMGN), listed on the NASDAQ, has a market capitalization of $181.50B. As of May 12, 2026, the stock is trading at $336.29 per share@else an unavailable price , offering investors a clear view of its current market value. Amgen Inc. is a prominent player in the industry sector, attracting both institutional and retail investors due to its performance and potential.
With a P/E ratio of 22.94, investors can assess the stock's valuation in comparison to its earnings. A P/E ratio is a crucial indicator for value investors, showing whether the stock is over or undervalued relative to its current earnings. Amgen Inc. also offers a dividend yield of 3%, making it an attractive option for income-focused investors who seek regular dividends.
Our Discounted Cash Flow (DCF) analysis reveals that Amgen Inc. (AMGN) may be undervalued compared to its intrinsic worth. However, to see the exact DCF fair value, please Login or Upgrade for access.
The proprietary SS Score for Amgen Inc. is a unique metric that analyzes the company's financial health and growth potential. The score takes into account critical factors such as revenue growth, net income, free cash flow (FCF) compound annual growth rate (CAGR), the trend of shares outstanding, and the debt-to-FCF ratio. This helps investors to make a more informed decision, as an undervalued stock might still have poor financial fundamentals.
To view the detailed SS Score for Amgen Inc., Login or Upgrade for access.
The Price to Free Cash Flow (P/FCF) ratio for Amgen Inc. is 21.03, offering insights into how much investors are paying for the company's free cash flow. A lower P/FCF ratio typically suggests that the stock is undervalued, while a higher ratio may indicate overvaluation.
In summary, Amgen Inc. (AMGN) has shown consistent financial performance, as illustrated by the financial charts above, which track its revenue growth, net income, free cash flow, and shares outstanding over the past several years. These metrics provide investors with key insights into the company's past and projected future performance. Investors should use the SS Score alongside the DCF Fair Value to make better-informed decisions about whether to buy or hold the stock.
*This analysis is for informational purposes only and does not constitute investment advice. Always read the company's 10-K filings and do your own research before making any investment decisions.
Whether Amgen Inc. (AMGN) is a good stock to buy depends on various factors, including its financial health, market conditions, and your investment strategy. Our analysis indicates that the stock may be undervalued compared to its intrinsic value. However, it is important to assess the SS Score and review the company's fundamentals before making any investment decisions.
The fair value of Amgen Inc. (AMGN) is determined through our Discounted Cash Flow (DCF) analysis. This value represents the intrinsic worth of the stock based on its expected future cash flows. To view the specific fair value, consider subscribing to our service for complete access.
The SS Score is a proprietary financial quality metric that assesses factors such as revenue growth, net income, free cash flow growth, and debt levels. It helps investors evaluate the overall financial health of Amgen Inc.. To access the full SS Score, consider upgrading your subscription.
Amgen Inc. is a significant player in the industry sector, with a market capitalization of $181.50B and a competitive P/E ratio of 22.94. Investors should compare these metrics with industry peers to gauge whether Amgen Inc. is outperforming or underperforming within its sector.
THOUSAND OAKS, Calif., May 7, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Bank of America Merrill Lynch Global Healthcare Conference at 10:00 a.m.
Freedom Broker upgraded Amgen (AMGN) to Buy from Hold with an unchanged price target of $375. Amgen’s Q1 results were “fully in line with our expectations, although the quarter is…
Erste Group analyst Hans Engel downgraded Amgen (AMGN) to Hold from Buy.
Erste Group analyst Hans Engel downgraded Amgen (AMGN) to Hold from Buy, saying the company’s sales growth will likely decline in 2026 and 2027. Amgen’s growth is lower than competitors,…
Amgen (AMGN) announced plans to invest an additional $300M in its U.S. manufacturing network to further advance U.S.-based production capacity, enhance next-generation technologies and support a relia...
Amgen said on Monday it was investing an additional $300 million in Puerto Rico to expand its U.S. manufacturing network.
Investment Strengthens American Manufacturing, Supply Chain Resilience and Next-Generation Technology THOUSAND OAKS, Calif., May 4, 2026 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced plans to i...
Guggenheim lowered the firm’s price target on Amgen (AMGN) to $340 from $351 and keeps a Neutral rating on the shares. The firm is updating its model following the company’s…
BofA raised the firm’s price target on Amgen (AMGN) to $307 from $304 and keeps an Underperform rating on the shares. The firm, which adjusted estimates in-line with recent launch…
Morgan Stanley raised the firm’s price target on Amgen (AMGN) to $332 from $326 and keeps an Equal Weight rating on the shares. Amgen posted an in-line Q1 on revenue,…
Truist raised the firm’s price target on Amgen (AMGN) to $327 from $325 and keeps a Hold rating on the shares after its inline Q1 results for revenue and a…
FY26 consensus $22.32. Raises FY26 revenue view to $37.1B-$38.5B from $37B-$38.4B, consensus $37.79B.
The biotechnology company reported a profit of $1.82 billion, driven by a 4% rise in product sales.
Reports Q1 revenue $8.6B, consensus $8.57B. “Our first quarter results demonstrate the strength of our business, with 16 brands achieving double-digit growth, enabling us to grow through expected pate...
16:03 EDT Amgen (AMGN) sees FY26 CapEx $2.6B; share repurchases not to exceed $3B
Amgen on Thursday reported first-quarter product sales rose 4%, helped by demand for cholesterol and rare disease medicines, and said it was moving forward with a broad development program for exper...
THOUSAND OAKS, Calif., April 30, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the first quarter of 2026.
Notable companies reporting after the market close, with earnings consensus, include Apple (AAPL), consensus $1.95… Amgen (AMGN), consensus $4.77… SandDisk (SNDK), consensus $14.62… Western Digital (W...
The U.S. Food and Drug Administration (FDA) is looking to deploy artificial intelligence to achieve real-time evaluation of clinical trial results to accelerate the time frame it takes to develop…
The U.S. Food and Drug Administration's Center for Drug Evaluation and Research on Monday proposed withdrawing approval of Amgen's drug for a group of rare autoimmune diseases, citing a lack of ...
Novartis, Amgen and Eli Lilly are among the pharmaceutical companies developing drugs to lower levels of a particularly bad form of cholesterol called Lp(a) and potentially prevent heart attacks. Lp(a...
THOUSAND OAKS, Calif., April 24, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its first quarter 2026 financial results on Thursday, April 30, 2026, after the close of t...
Organizational Changes Further Emphasize Integration of Biology and Technology THOUSAND OAKS, Calif., April 22, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the retirement of David M.
Amgen's lung cancer drug tarlatamab has won approval from China's National Medical Products Administration, its development and commercialisation partner BeOne Medicines said on Friday on WeChat.
Below estimates were sourced from SimplyWallSt and are intended for educational purposes only as a baseline for the analysis.
| Year | FCF Estimate | % | # Analysts |
|---|---|---|---|
| 2026 | 12.72B | Analyst x6 | |
| 2027 | 13.88B | 9.13% | Analyst x7 |
| 2028 | 14.20B | 2.30% | Analyst x7 |
| 2029 | 14.94B | 5.20% | Analyst x6 |
| 2030 | 16.27B | 8.89% | Analyst x6 |
| 2031 | 16.85B | 3.59% | Est @3.6% |
| 2032 | 17.41B | 3.32% | Est @3.3% |
| 2033 | 17.95B | 3.11% | Est @3.1% |
| 2034 | 18.45B | 2.78% | Est @2.8% |
| 2035 | 18.95B | 2.69% | Est @2.7% |
Below are the FCF estimates with the discount factor and the calculated present value with the terminal value that led the results above.
| Year | FCF | Discount Factor | PV of Future FCF |
|---|---|---|---|
| 2024A | 10.39B | 1.00 | 10.39B |
| 2025A | 8.10B | 1.00 | 8.10B |
| 2026E | 12.72B | 1.08 | 11.81B |
| 2027E | 13.88B | 1.16 | 11.97B |
| 2028E | 14.20B | 1.25 | 11.37B |
| 2029E | 14.94B | 1.34 | 11.11B |
| 2030E | 16.27B | 1.45 | 11.23B |
| 2031E | 16.85B | 1.56 | 10.81B |
| 2032E | 17.41B | 1.68 | 10.37B |
| 2033E | 17.95B | 1.81 | 9.93B |
| 2034E | 18.45B | 1.95 | 9.48B |
| 2035E | 18.95B | 2.10 | 9.04B |
| Terminal | 374.76B | 2.10 | 178.79B |
The information given by Studying Stocks and provided in the web and/or mobile applications (Platforms) is only factual information and should not be considered financial advice.
Any information contained in this website has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
When creating an account, you acknowledge that you are:
We retain the right to cancel your account for any reason, or refuse your account creation request.
The information on our Platforms is not comprehensive and is intended to provide a summary of the subject matter covered. While we use all reasonable attempts to ensure the accuracy and completeness of the data and information on our Platforms, to the extent permitted by law, we make no warranty regarding the information on these Platforms. You should monitor any changes to the information contained on these Platforms.
Furthermore we make no commitments in regards to the minimum amount of uptime that our platforms will maintain, although we will make ever reasonable attempt to ensure that the platforms are operational. Therefore, any reference of "latest", "current" and related words about the financial data presented here may not be up to date with the financial markets or represent reality of the information.
We are not liable to you or anyone else if interference with or damage to your computer systems occurs in connection with the use of these Platforms or a linked website. You must take your own precautions to ensure that whatever you select for your use from our Platforms is free of viruses or anything else (such as worms or Trojan horses) that may interfere with or damage the operations of your computer systems.
We may, from time to time and without notice, change or add to the Platforms (including the Terms) or the information, products or services described in it. However, we do not undertake to keep the Platforms updated. We are not liable to you or anyone else if errors occur in the information or the Platforms is not up-to-date.
Our Platforms may contain links to websites operated by third parties. Those links are provided for convenience and may not remain current or be maintained. Unless expressly stated otherwise, we do not endorse and are not responsible for the content on those linked websites and have no control over or rights in those linked websites.
These Platforms are for your personal, non-commercial use only. You may not modify, copy, distribute, transmit, display, perform, reproduce, publish, license, commercially exploit, create derivative works from, transfer, or sell any Content, software, products or services contained within these Platforms. You may not use these Platforms, or any of its Content, to further any commercial purpose, including any advertising or advertising revenue generation activity on your own website.
You must not do any act that we would deem to be inappropriate, is unlawful or is prohibited by any laws applicable to these Platforms, including but not limited to:
If we allow you to post any information to our Platforms, we have the right to take down this information at our sole discretion and without notice.
To the maximum extent permitted by law, we make no warranties or representations about these Platforms or the Content, including but not limited to warranties or representations that they will be complete, accurate or up-to-date, that access will be uninterrupted or error-free or free from viruses, or that these Platforms will be secure.
We reserve the right to restrict, suspend or terminate without notice your access to these Platforms, any Content, or any feature of these Platforms at any time without notice and we will not be responsible for any loss, cost, damage or liability that may arise as a result.
To the maximum extent permitted by law, in no event shall we be liable for any direct and indirect loss, damage or expense – irrespective of the manner in which it occurs – which may be suffered due to your use of our Platforms and/or the information or materials contained on it, or as a result of the inaccessibility of these Platforms and/or the fact that certain information or materials contained on it are incorrect, incomplete or not up-to-date.
This website utilises cookies. If you do not have cookies enabled in your web browser some functions of the site may not work as intended.